Johnson & Johnson Q1 Beats Guidance Raise

Johnson & Johnson reported Q1 2026 adjusted EPS $2.70, beating consensus $2.68, and revenue $24.1bn, up 9.9% YoY.
Company raised full‑year 2026 guidance to $11.45‑$11.65 EPS and $100.3‑$101.3bn sales, midpoint matching analyst consensus.
Innovative Medicine sales grew 7.4% driven by DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA and SPRAVATO, offset by STELARA and IMBRUVICA.
MedTech sales rose 4.6% led by electrophysiology, Abiomed, Shockwave cardiovascular and orthopaedic trauma products; free cash flow dropped to $1.5bn from $3.4bn.